991 / 1084
Negative trials
with targeted agents
have
substantially out numbered the
positive trials
(the ToGA, REGARD,
and RAINBOW trials) in GAC in the
past decade
Major factors accounting for this negative
outcome may be
(1)
many trials did not select the patient
population based on specific target
,
(2)
inaccurate biomarker for
patient selection
(i.e., HER2, FISH vs.
HER2 IHC)
03/28/2017